Trial Profile
A Phase 1/1B Dose-Escalation Study to Determine the Safety and Tolerability of SCH 717454 Administered in Combination With Chemotherapy in Pediatric Subjects With Advanced Solid Tumors (Protocol No. 05883)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Robatumumab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Ifosfamide; Irinotecan; Temozolomide; Vincristine
- Indications Ewing's sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 14 Feb 2013 Actual end date changed from Sep 2010 to Dec 2010 as reported by ClinicalTrials.gov.
- 21 Feb 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 04 Aug 2011 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov.